Key result
Macrophage-targeted nanoparticles show strong potential to reduce atherosclerotic plaque burden and inflammation.
Authors
No takes yet. Share an insight, caveat, or question.
Macrophage-targeted nanotherapeutics represent a promising strategy to reduce plaque burden and inflammation in atherosclerosis.
Xu et al. (2025) conducted a review in Atherosclerosis. Nano-therapeutics targeting the macrophage-based microenvironment was evaluated. Macrophage-targeted nanotherapeutic approaches and intelligent responsive nanoparticles demonstrate significant potential for treating atherosclerosis by reducing plaque burden and inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: